Nov 29, 2022 · D3S-001 is a selective and covalent KRAS G12C small molecule inhibitor designed to enhance KRAS G12C target engagement. In preclinical investigation, D3S-001 has demonstrated high potency, CNS penetration property and capability to achieve complete KRAS G12C target engagement at predicted clinically relevant dose.

D3S-001 is a next-generation KRAS G12C inhibitor designed to enhance clinical outcomes by improving KRAS G12C target engagement. In preclinical investigations, D3S-001 has demonstrated high covalent potency, CNS penetration properties, and the capability to rapidly and completely engage the KRAS G12C target at clinically relevant doses.

Shanghai, China, Sep 12, 2024 — D3 Bio today announced that it will present clinical data from its lead oncology program, D3S-001, a second-generation KRAS G12C inhibitor with best-in-class potential, in a mini oral presentation at the ESMO Congress 2024 on September 14, 2024, in Barcelona, Spain.

Today, D3 Bio announced that the company received IND (Investigational New Drug) clearance from US FDA for D3S-001, a potent and selective small molecule inhibitor for the mutant KRAS G12C protein at the end of March.

Today, D3 Bio announced that the company received IND (Investigational New Drug) clearance from US FDA IND for D3S-001, a potent and selective small molecule inhibitor for the mutant KRAS G12C protein in the end of March.

Mar 31, 2023 · The Company received Orphan Drug Designation (ODD) from Office of Orphan Products Development (OOPD), FDA, to D3S-001 for treatment of patients with advanced pancreatic cancer harboring KRAS p.G12C mutant protein.

Oct 31, 2022 · D3S-001 is a small molecule inhibitor that selectively and irreversibly inhibits the KRAS G12C mutant protein, blocking its interaction with downstream effectors, such as the RAF serine/threonine protein-kinase, thereby preventing the propagation of oncogenic signaling.

D3L-001, for treatment of eligible patients with locally advanced or metastatic HER2-positive breast cancer. The purpose of this policy is to describe the requirements for Expanded Access to D3 Bio’s investigational products under the 21 st Century Cures Act for the use of investigational drugs outside of clinical trial settings, when certain ...

The funding will be allocated to expedite the development of D3 Bio's assets through preclinical and clinical stages, with a particular focus on accelerating the global clinical trial of D3S-001, a new generation small molecule KRAS G12C inhibitor with the best-in-class potential.